Amgen’s most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $110.00 short put and a strike $100.00 long put offers a potential 5.26% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $110.00 by expiration. The full premium credit of $0.50 would be kept by the premium seller. The risk of $9.50 would be incurred if the stock dropped below the $100.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 65.44 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen Reports Strong Numbers, But Better Days May Be Coming
Fri, 25 Oct 2013 14:54:24 GMT
Motley Fool – Amgen saw rapid growth for Xgeva and Prolia in the third quarter, but future growth may be driven by Asian partnerships, new drugs, and Amgen’s acquisition of Onyx Pharmaceuticals.
Can AbbVie Hold Off Amgen and Pfizer?
Thu, 24 Oct 2013 19:44:04 GMT
Motley Fool – AbbVie has relied on Humira for rheumatoid arthritis for years, but with its patent expiring within three years, AbbVie will have to find answers to go up against the longer-lived patent protection that …
Celgene Earnings Beat Estimates, But Stock Dips
Thu, 24 Oct 2013 15:42:00 GMT
Investor’s Business Daily – Celgene Earnings Beat Estimates, But Stock Dips
Celgene’s New Multiple Myeloma Drug Is Kicking Amgen’s Ass
Thu, 24 Oct 2013 12:38:00 GMT
TheStreet – CELG data by YCharts SUMMIT, NJ ( TheStreet ) — Celgene issued another “beat and raise” earnings report for the third quarter earnings — pretty much standard operating procedure these days …
3 Takeaways From Amgen’s Earnings Report
Thu, 24 Oct 2013 12:28:00 GMT
Motley Fool – Investors have a lot to chew on after Amgen’s third quarter earnings. This should help them digest the results.
Also on Market Tamer…
Follow Us on Facebook